about
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesA novel chimeric promoter that is highly responsive to hypoxia and metals.The targeting expression of the vascular endothelial growth factor gene in endothelial cells regulated by HRE.ppET-1.Adenoviral targeting of gene expression to tumors.Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cellsClostridia in cancer therapy.Tumor hypoxia: a target for selective cancer therapy.Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genesOncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo.Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenograftsGene therapy targeting to tumor endothelium.Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo.Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.Hypoxia-Sensitive Materials for Biomedical Applications.Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.Effects of YC-1 targeting hypoxia-inducible factor 1 alpha in oesophageal squamous carcinoma cell line Eca109 cells.Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment.Robust hypoxia-selective regulation of a retinal pigment epithelium-specific adeno-associated virus vectorp53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro.A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas.Effect of hypoxia on Ad5 infection, transgene expression and replication.A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy.A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia.A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia-reperfusion in vivo.A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
P2860
Q21144267-38E83060-77FC-4854-B653-CA9F516972F0Q33233475-D6D4669A-D724-4C40-9711-29FD844118C6Q33383262-03FF2B04-C7D8-4BD1-808D-51978F17AE9EQ33862714-5264D5ED-7173-474B-94C9-9342CD0A25F3Q33881694-84608F7D-D3D9-4B6F-A06C-75689794A402Q34307573-0A2F6D35-E25B-4CF1-ABD4-FB50CECD9096Q35602696-474B8525-2110-4E9E-B853-B7D306887AFAQ36353524-8291FB23-2D61-4CBE-BC27-AF12951C9A3CQ36385632-AA2C0B87-24A9-48FB-96C4-BDC683E64B47Q36437378-E415EB5D-397F-4B4A-A7F5-BD64465A16FFQ36609637-4C9DAD22-2100-4DD6-88E4-37AA1ED5C8ABQ36649681-9EFAA0EE-6349-410A-8704-3DA829A429CAQ37104879-98EA5D73-4689-483C-AC46-61C7A96A7EB9Q37586895-03D0FAD2-EEC1-4BD6-87D6-6452DCFAED84Q38685276-FA6C247B-1E91-4830-909E-4ABBEF623B55Q38754932-841C89E6-2097-46A0-890C-BB2A137AFF31Q38824983-E62E67CD-880C-4556-82F4-5B4482F0F0E8Q39238726-242B8DF9-5D98-44D7-8D3A-D61C50FB0E34Q39639721-9C28C633-8483-45B4-95D8-68CE3DFDAA78Q39756181-4FAA8CE0-D2EF-4449-A2B0-AD53C4271714Q39778777-B7A15B70-8FFC-4016-B47E-D48DE68E45A3Q39993165-C8D26E2B-5986-464A-83B7-F836B6ED19FFQ40003426-E5612AFA-2CB7-4379-AF87-6A125D8E59A3Q40174557-36CD9223-D000-4FFE-B810-19AB8ABE9FA1Q40420346-587F327F-04CA-4031-97B9-41254A1042FEQ40462233-72624CE2-7749-412A-BC24-BC89F6FC642DQ41817953-9E3E1BA5-C531-4B2D-91CE-500BA5A219ADQ41925534-9E92EC43-41F3-4AC1-929F-778EEB707DE1Q45882286-7292641C-5AAB-4A89-8480-93B22CA552BDQ45889472-15604C40-1EFB-4EA1-839C-CDAF71A91703Q47549547-C9FC5BDB-9C90-43BE-AC3C-FD94555202DC
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Hypoxia-mediated tumour targeting.
@en
Hypoxia-mediated tumour targeting.
@nl
type
label
Hypoxia-mediated tumour targeting.
@en
Hypoxia-mediated tumour targeting.
@nl
prefLabel
Hypoxia-mediated tumour targeting.
@en
Hypoxia-mediated tumour targeting.
@nl
P2093
P2860
P356
P1433
P1476
Hypoxia-mediated tumour targeting.
@en
P2093
H Spearman
S Kingsman
P2860
P2888
P304
P356
10.1038/SJ.GT.3301944
P577
2003-04-01T00:00:00Z